NEO (NeoGenomics) Total Current Liabilities: $84.6 Mil (As of Mar. 2026)


NEO NeoGenomics Inc NEO
71 GF Score
Price $14.25
GF Value $16.58
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is NeoGenomics Total Current Liabilities?

NeoGenomics NEO +0.56% 71 Total Current Liabilities is $84.6 Mil as of Mar. 2026. GuruFocus rates NEO with a GF Score™ of 71/100 and a GF Value™ of $16.58 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. NeoGenomics's total current liabilities for the quarter that ended in Mar. 2026 was $84.6

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

NeoGenomics Total Current Liabilities Related Terms

NeoGenomics Total Current Liabilities Historical Data

* Premium members only.

The historical data trend for NeoGenomics's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NeoGenomics Total Current Liabilities Chart

NeoGenomics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 87.23 89.93 96.30 301.24 88.30

NeoGenomics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 279.70 100.12 97.87 88.30 84.59
NEO
71GF Score
NeoGenomics Inc NEO
Total Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NeoGenomics Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

NeoGenomics's Total Current Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=35.093+4.776
+Other Current Liabilities+Current Deferred Liabilities
=47.58+0.851
=88.3

NeoGenomics's Total Current Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=38.625+4.828
+Other Current Liabilities+Current Deferred Liabilities
=40.576+0.561
=84.6

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

What does a Total Current Liabilities of $84.6 Mil mean?
NeoGenomics (NEO) has a Total Current Liabilities of $84.6 Mil as of Mar. 2026. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for NeoGenomics and its competitors.
Is NeoGenomics' Total Current Liabilities too high?
NeoGenomics' current Total Current Liabilities is $84.6 Mil. Overall, NeoGenomics has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does NeoGenomics' Total Current Liabilities compare to WGS and CDNA?
NeoGenomics' Total Current Liabilities of $84.6 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Liabilities for a Medical Diagnostics & Research company?
A good Total Current Liabilities depends on the Medical Diagnostics & Research industry context. However, Total Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Liabilities mean?
A high Total Current Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for NeoGenomics and its competitors. NeoGenomics's current Total Current Liabilities is $84.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeoGenomics stock overvalued right now?
Based on GuruFocus' analysis, NeoGenomics (NEO) is currently considered Modestly Undervalued. The stock's GF Value™ is $16.58, compared to a current price of $14.25 — trading 14.1% below its estimated fair value. The current Total Current Liabilities is $84.6 Mil. NeoGenomics' overall GF Score™ is 71/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Liabilities calculated?
Total Current Liabilities is calculated from a company's financial statements. For NeoGenomics (NEO), the current Total Current Liabilities is $84.6 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NeoGenomics (NEO) Overvalued in 2026?

Based on GuruFocus' analysis, NeoGenomics stock appears to be undervalued. The current stock price of $14.25 is trading 14.1% below its estimated GF Value™ of $16.58. GuruFocus considers NeoGenomics to be Modestly Undervalued.

Key valuation signals for NEO:

  • Total Current Liabilities: $84.6 Mil
  • GF Value™: $16.58 vs. price of $14.25 (14.1% below fair value)
  • GF Score™: 71/100 with 6 warning signs

No single metric tells the full story. See the NEO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

NeoGenomics Business Description

Other Exchanges NEO:MexicoNG9:Germany
Address 9490 NeoGenomics Way, Fort Myers, FL, USA, 33912
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
71GF Score

Get the complete analysis for NEO

Total Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$14.25
Price
$16.58
GF Value